Login / Signup

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.

Ryotaro BouchiMasahiro TerashimaYuriko SasaharaMasahiro AsakawaTatsuya FukudaTakato TakeuchiYujiro NakanoMasanori MurakamiIsao MinamiHajime IzumiyamaKoshi HashimotoTakanobu YoshimotoYoshihiro Ogawa
Published in: Cardiovascular diabetology (2017)
Our data suggest that luseogliflozin could reduce the EFV in parallel with the improvement of systemic micro-inflammation and the reduction of body weight in Japanese patients with type 2 diabetes. The reduction of muscle mass after the administration of SGLT2 inhibitors may require a particular attention. Trial registration umin.ac.jp, UMIN000019072.
Keyphrases
  • body weight
  • oxidative stress
  • adipose tissue
  • study protocol
  • working memory
  • clinical trial
  • electronic health record
  • phase iii
  • big data
  • phase ii
  • fatty acid
  • randomized controlled trial
  • open label
  • data analysis